This Houston AI expert is calling the city's business leaders to step up when it comes to AI. Photo via Getty Images

Houston's industrial and energy landscapes are at a pivotal juncture. We're witnessing an undeniable gap in technical expertise that's hard to ignore. At the same time, there's a rising wave of artificial intelligence-driven solutions that could be the answer we've been searching for.

The expertise shortfall

Our city has always been the pulse of the energy and industrial sectors. We've grown, we've innovated, and we've set benchmarks for the world. But as we steer ahead, a pressing concern looms large: the dwindling pool of technical expertise. This isn't about not having enough hands-on deck; it's about not having the right hands to navigate our industries' intricate machinery and complex systems. Pipelines, refineries, renewable energy solutions – these are the cornerstones of Houston's legacy, and we need adept professionals to keep pushing boundaries.

AI: The game changer

But here's the thing: Houston isn't just the hub of traditional energy and industrial operations. We're sitting on a goldmine of data, real-world use cases, and the drive to innovate. Enter AI. It's not just tech jargon; it's a tool with untapped potential, waiting to be harnessed.

We have the industry foundation, the data reservoirs, and the prime use cases that make AI not just viable, but indispensable. Houston is uniquely positioned to lead this AI revolution. We're not just talking about implementing AI; we're talking about innovating with AI, tailoring it to our city's and our industry’s needs, and setting a precedent for the global stage. This is where the challenge meets opportunity. We have what it takes to mold AI solutions that can fill the expertise gap and propel our industries to new heights.

Houston's call to action

If there's any city poised to be the epicenter of AI, it's Houston. We've always been pioneers, and this is our chance to solidify our position as global leaders once again. Houston has everything: the industries, the data, the use cases, and most importantly, the ambition. The question isn't whether we can usher in an era of AI-enhanced operations; it's how swiftly we can do it.

Our city is on the brink of something monumental. It's time we leverage AI to not just bridge the expertise gap but to create an industrial future that's resilient, innovative, and unparalleled. So, to industry leaders, stakeholders, and visionaries, here's the pitch: Houston's at a crossroads, and the path we choose now will shape our legacy for decades. It's time we lean into AI, harness its potential, and ensure that our city remains the powerhouse it's always been.

However, this one question remains: Are you, this city's industry leaders, ready to redefine Houston's legacy in the face of an expertise challenge, or will you stick to the status quo and risk stagnation?


------

Marty Dytrych is the co-founder and CEO of Industrial Data Labs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."